# Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

> **NCT02843945** · PHASE1,PHASE2 · RECRUITING · sponsor: **CivaTech Oncology** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DEVICE:** Directional Brachytherapy Source Implant

## Key facts

- **NCT ID:** NCT02843945
- **Lead sponsor:** CivaTech Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-05-31
- **Primary completion:** 2027-10-29
- **Final completion:** 2028-10-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843945, "Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02843945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*